Substance Abuse Treatment, Prevention, and Policy (Jul 2023)

Association between toxic drug events and encephalopathy in British Columbia, Canada: a cross-sectional analysis

  • Chloé G. Xavier,
  • Margot Kuo,
  • Roshni Desai,
  • Heather Palis,
  • Gemma Regan,
  • Bin Zhao,
  • Jessica Moe,
  • Frank X. Scheuermeyer,
  • Wen Qi Gan,
  • Soha Sabeti,
  • Louise Meilleur,
  • Jane A. Buxton,
  • Amanda K. Slaunwhite

DOI
https://doi.org/10.1186/s13011-023-00544-z
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Background Encephalopathy can occur from a non-fatal toxic drug event (overdose) which results in a partial or complete loss of oxygen to the brain, or due to long-term substance use issues. It can be categorized as a non-traumatic acquired brain injury or toxic encephalopathy. In the context of the drug toxicity crisis in British Columbia (BC), Canada, measuring the co-occurrence of encephalopathy and drug toxicity is challenging due to lack of standardized screening. We aimed to estimate the prevalence of encephalopathy among people who experienced a toxic drug event and examine the association between toxic drug events and encephalopathy. Methods Using a 20% random sample of BC residents from administrative health data, we conducted a cross-sectional analysis. Toxic drug events were identified using the BC Provincial Overdose Cohort definition and encephalopathy was identified using ICD codes from hospitalization, emergency department, and primary care records between January 1st 2015 and December 31st 2019. Unadjusted and adjusted log-binomial regression models were employed to estimate the risk of encephalopathy among people who had a toxic drug event compared to people who did not experience a toxic drug event. Results Among people with encephalopathy, 14.6% (n = 54) had one or more drug toxicity events between 2015 and 2019. After adjusting for sex, age, and mental illness, people who experienced drug toxicity were 15.3 times (95% CI = 11.3, 20.7) more likely to have encephalopathy compared to people who did not experience a drug toxicity event. People who were 40 years and older, male, and had a mental illness were at increased risk of encephalopathy. Conclusions There is a need for collaboration between community members, health care providers, and key stakeholders to develop a standardized approach to define, screen, and detect neurocognitive injury related to drug toxicity.

Keywords